Brief: Poxel: FDA Grants Orphan Drug Designation To PXL770

Poxel SA

03/10/2022 06:34

Oct 3 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL ANNOUNCES PXL770 GRANTED ORPHAN DRUG DESIGNATION
FROM U.S.
FDA FOR AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    * COMPLETION OF PRECLINICAL STUDIES SUPPORT POTENTIAL TO
ADVANCE
PXL770 INTO PHASE 2 DEVELOPMENT FOR ADPKD
    * COMPELLING PRECLINICAL EFFICACY DATA CONFIRM STRATEGIC
FOCUS FOR
PXL770 IN RARE METABOLIC DISEASES
    * WE HAVE INITIATED DEVELOPMENT PROGRAM PLANNING AND FURTHER
REGULATORY INTERACTIONS

Source text for Eikon:  ID:nBw6snxl3a 
Further company coverage:  POXEL.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))